Abstract
Objective: To confirm the in vivo anti-myeloma activity of I3MO (Indirubin-3' -monoxime) in primary patient samples, a patient-derived xenograft (PDX) zebrafish model of MM was utilized. Methods: zebrafish embryos were obtained by the natural spawning of Tubingen strain and incubated at 28°C in embryo medium. The purified CD138+ MM cells fluorescently labeled with Calcein-AM or Dil were injected into the perivitelline space of each embryo of zebrafish at 48 hpf. Engrafted embryos were transferred into 24-well plates and incubated at 28°C in freshly prepared E3 medium containing DMSO, BTZ, I3MO. At 24 hours post injection (hpi), engrafted embryos were detected by fluorescent microscopy to qualify the positive areas with calcein (green) or Dil (red). Results:1. The zebrafish PDX model of MM was successfully applied in the drug effects evaluation. 2. The results in vivo demonstrated that BTZ or I3MO eliminates the engraftment and growth of MM cells in zebrafish embryos (p<0.05). Conclusion: The zebrafish is an ideal model to investigate the cytotoxicity in vivo of compounds on primary MM patient samples.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
